Liminal BioSciences Inc.

NasdaqCM:LMNL Stock Report

Market Cap: US$13.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Liminal BioSciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Liminal BioSciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth27.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule

Sep 02

Liminal BioSciences ends CDMO agreement for $33M cost savings

Aug 25

Liminal BioSciences discontinues fezagepras development

Jul 21

FDA grants approval to Liminal BioSciences' Ryplazim treatment

Jun 04

Liminal shares slide after plans to stop fezagepras development

May 28

Liminal Biosciences subsidiary receives FDA nod for US-based plasma collection centre

Jan 12

Liminal BioSciences Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 13

FDA extends review period for Liminal Bio's Ryplazim application

Nov 09

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Liminal BioSciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:LMNL - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20230-28-36-36N/A
3/31/20231-26-35-35N/A
12/31/20220-29-32-32N/A
9/30/20220-31-38-38N/A
6/30/20221-36-84-84N/A
3/31/20220-42-86-86N/A
12/31/20211-44-100-100N/A
9/30/20211-48-114-114N/A
6/30/20211-49-75-74N/A
3/31/20211-35-75-74N/A
12/31/20201-48-78-76N/A
9/30/20201-75-87-85N/A
6/30/20202-94-86-85N/A
3/31/20203-232-109-105N/A
12/31/20191-150-104-99N/A
9/30/2019-8-299-95-89N/A
6/30/20193-298-90-84N/A
3/31/201923-194-73-68N/A
12/31/201825-197-88-82N/A
9/30/201843-131-91-85N/A
6/30/201855-118-112-105N/A
3/31/201839-115-128-120N/A
12/31/201722-112-133-123N/A
9/30/201737-109-139-129N/A
6/30/201716-119-130-118N/A
3/31/201716-112N/A-114N/A
12/31/201616-101N/A-98N/A
9/30/201626-74N/A-76N/A
6/30/201628-58N/A-66N/A
3/31/201628-48N/A-59N/A
12/31/201525-51N/A-46N/A
9/30/201521-31N/A-42N/A
6/30/201518-41N/A-36N/A
3/31/201519-5N/A-27N/A
12/31/2014236N/A-26N/A
9/30/201418-10N/A-25N/A
6/30/2014214N/A-25N/A
3/31/201422-23N/A-19N/A
12/31/201321-16N/A-17N/A
9/30/201324-8N/A-9N/A
6/30/201326-1N/A-3N/A
3/31/2013273N/A-4N/A
12/31/2012230N/A-2N/A
9/30/2012233N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LMNL's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if LMNL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if LMNL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LMNL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if LMNL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LMNL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/27 23:49
End of Day Share Price 2023/09/25 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Liminal BioSciences Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Doug CooperBeacon Securities Limited
Antonia BorovinaBloom Burton & Co.
Dewey SteadmanCanaccord Genuity